Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

By W. Sandborn, Subrata Ghosh, J. Panés, I. Vranic, C. Su, S. Rousell, W. Nieżychowski. New England Journal of Medicine, 2012

765 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/2d8b145d5875f93b7d6995eaa5544ec8315e2396

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Powrie
2. M. Pohin
3. J. O’Shea
4. M. Friedrich

In Rheumatology

1. I. McInnes
2. J. O’Shea
3. S. Gaffen

Citations in the corpus

• The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention (2015, background): “ulcerative colitis (69), but not in Crohn’s disease (70).”
• Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, background): “JAK inhibition targeting multiple cytokines Tofacitinib (pan-JAK inhibitor) (approved for moderate-to-severe UC) (Sandborn et al., 2012)”